TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

SKYE Stockholders with Large Losses Should Contact Robbins LLP for Information About Leading the Skye Bioscience, Inc. Class Action Lawsuit

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Robbins Llp
SKYE Stockholders with Large Losses Should Contact Robbins LLP for Information About Leading the Skye Bioscience, Inc. Class Action Lawsuit

Skye Bioscience faces a class action lawsuit alleging misleading investors about its lead drug candidate nimacimab's effectiveness, with stock price dropping 60% after revealing poor clinical trial results.

Insights
SKYE   negative

Stock price fell 60% after revealing that drug candidate did not achieve primary weight loss endpoint, suggesting potential failure of key product and potential investor deception